Lantern Pharma

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Our mission is to use AI and ML to discover novel, targeted cancer therapies and deliver meaningful clinical outcomes to patients.

Our vision is to transform cancer treatment into a personalized experience for patients, with the goal of transforming cancer into a manageable, curable disease.

Lantern Pharma has been awarded numerous awards including the National Institutes of Health Pioneer Award and the National Cancer Institute Transformative Research Award.